Method for preparing stable emulsifiable concentrate of abamectin, pyriproxyfen, and tolfenpyrad for pest control

Abstract

Exemplary embodiments of the present disclosure are directed towards Method for preparing stable emulsifiable concentrate of Abamectin, Pyriproxyfen, and Tolfenpyrad for pest control. The method for preparing a stable, high-performance emulsifiable concentrate (EC) agrochemical formulation comprising multiple active ingredients with distinct modes of action. The method includes receiving and analyzing raw materials, charging solvents into a formulation tank, and sequentially adding additives, active ingredients, and emulsifiers under controlled agitation and temperature conditions to ensure complete dissolution, uniform emulsification, and product stability. The process further involves filtration, in-process quality control (IPC) testing, and final packaging after achieving specification compliance. The invention enhances formulation clarity, storage stability, and batch consistency, while the resulting product offers broad-spectrum pest control, reduced spraying frequency, resistance management, and crop safety across vegetables, cotton, tea, and fruit crops. This optimized process ensures high yield, extended residual activity, and superior field performance. FIG 3

Description

TECHNICAL FIELD

[001] The present disclosed subject matter relates to agrochemical formulations andpesticide technology, more particularly to a method for preparing a stableemulsifiable concentrate (EC) composition comprising Abamectin, Pyriproxyfen, andTolfenpyrad as active ingredients. More particularly, the present disclosure relates toa Method for Preparing Stable Emulsifiable Concentrate of Abamectin, Pyriproxyfen,and Tolfenpyrad for Pest Control.BACKGROUND

[002] Conventional emulsifiable concentrate (EC) formulations containing multipleactive ingredients often face significant challenges related to physical and chemicalinstability. Incompatibility among actives, solvents, and emulsifiers can lead to issuessuch as phase separation, crystallization, sedimentation, or turbidity during storage orupon dilution. These instabilities adversely affect the appearance, emulsificationefficiency, and biological performance of the formulation in field applications.

[003] Differences in polarity, solubility, and volatility among active componentsfurther complicate the formulation process. In many existing methods, improperselection of solvent systems and emulsifier combinations results in incompletedissolution of actives and non-uniform dispersion within the concentrate.

[004] Additionally, variations in agitation speed, temperature control, and sequenceof addition during manufacturing can lead to inconsistency in viscosity, specificgravity, and emulsion stability across production batches.

[005] Another limitation of conventional formulation processes is the lack of in-processcontrol (IPC) and real-time analytical monitoring. This often results in batch-to-batchvariability, reduced yield, and poor reproducibility at an industrial scale.

[006] Therefore, there exists a need for a systematic and optimized formulationmethod that ensures complete dissolution of actives, enhanced emulsification, andlong-term storage stability.

[007] In the light of aforementioned discussion, there is issues by providing acontrolled process sequence incorporating optimized solvent and emulsifier ratios,temperature regulation, and real-time quality verification to achieve a uniform, stable,and high-performance agrochemical formulation suitable for large-scale productionand consistent field efficacy.SUMMARY

[008] The following presents a simplified summary of the disclosure in order toprovide a basic understanding of the reader. This summary is not an extensiveoverview of the disclosure and it does not identify key / critical elements of theinvention or delineate the scope of the invention. Its sole purpose is to present someconcepts disclosed herein in a simplified form as a prelude to the more detaileddescription that is presented later.

[009] Exemplary embodiments of the present disclosure are directed towards aMethod for preparing stable emulsifiable concentrate of abamectin, Pyriproxyfen, andTolfenpyrad for pest control.

[0010] Another objective of the present disclosure is directed towards the presentinvention provides a method for preparing a stable, high-performance emulsifiableconcentrate (EC) agrochemical formulation through a precisely controlled processsequence.

[0011] Another objective of the present disclosure is directed towards the method isinvolving receiving, analyzing, and approving technical materials, solvents, andemulsifiers in accordance with predefined specifications; charging a controlledproportion of solvent into a formulation tank.

[0012] Another objective of the present disclosure is directed towards initiatingagitation under regulated temperature conditions for ensuring homogeneous mixing.

[0013] Another objective of the present disclosure is directed towards furtherincluding incorporating additives such as antioxidants and UV absorbers forimproving formulation stability and shelf-life.

[0014] Another objective of the present disclosure is directed towards adding activeingredients and emulsifiers sequentially in optimized ratios under continuous stirringfor enhancing miscibility, emulsification efficiency, and product clarity; andperforming fine filtration and in-process control (IPC) testing for obtaining a uniformand defect-free concentrate.

[0015] Another objective of the present disclosure is directed towards In addition toproviding manufacturing robustness, the invention is offering multiple agronomic andeconomic advantages enabling broad-spectrum pest control through three distinctmodes of action (MoA), enhancing resistance management, reducing sprayingfrequency and lowering overall application cost.

[0016] Another objective of the present disclosure is directed towards the formulationis exhibiting rapid knockdown, prolonged residual activity, and reproductivesuppression of target pests, thereby ensuring both immediate and extended protectionunder field conditions..

[0017] Another objective of the present disclosure is directed towards Thecomposition is further exhibiting excellent crop safety and versatility, beingapplicable to vegetables (tomato, chili, cucurbits, beans), cotton, tea, and fruit crops(citrus, grapes, and pomegranate).

[0018] Another objective of the present disclosure is directed towards the formulationis providing protection during critical crop growth stages such as flowering andfruiting, thereby minimizing yield losses caused by sucking and chewing pests.

[0019] Another objective of the present disclosure is directed towards the inventionis contributing to yield and quality enhancement by protecting tender leaves, flowers,and fruits, thereby improving photosynthetic efficiency, maintaining canopy health,and promoting better fruit setting.

[0020] Another objective of the present disclosure is directed towards optimizingsolvent-emulsifier balance, agitation parameters, temperature control, and sequenceof addition, the present invention is achieving a robust, scalable, and cost-efficientmethod for producing a stable agrochemical emulsifiable concentrate capable ofensuring consistent field performance, effective resistance management, andenhanced economic returns to growers.

[0021] Another objective of the present disclosure is directed towards, Enhancingcrop safety and versatility by enabling application across diverse crops and protectingplants during critical growth stages.

[0022] Another objective of the present disclosure is directed towards, Improvingyield and quality by protecting tender leaves, flowers, and fruits, thereby promotingbetter photosynthesis, canopy health, and fruit setting.

[0023] Another objective of the present disclosure is direct towards, Achieving astable, homogeneous, and storage-resistant formulation by optimizing solvent-emulsifier ratios, temperature conditions, and sequence of ingredient addition

[0024] According to an exemplary embodiment of the present disclosure, receivingand quality-checking technical-grade actives, solvents, and emulsifiers for purity,assay, and moisture compliance.

[0025] According to an exemplary embodiment of the present disclosure, chargingabout 70-80 % of the total solvent into a formulation tank and initiating agitation at150-250 rpm while maintaining temperature between 25 °C and 30 °C to form auniform solvent base.

[0026] According to an exemplary embodiment of the present disclosure addingantioxidants and UV absorbers under continuous stirring until completely dissolvedto form a clear base solution.

[0027] According to an exemplary embodiment of the present disclosure,sequentially introducing Abamectin equivalent to 1.5 % w / w (C48H72O14 (mixture ofB1a and B1b components), Pyriproxyfen equivalent to 9 % w / w (C20H19NO3), andTolfenpyrad equivalent to 8 % w / w(C21H22ClN3O2) into the solvent base whilemaintaining temperature below 35 °C to prevent degradation.

[0028] According to an exemplary embodiment of the present disclosure, continuingagitation until a clear, homogeneous solution of actives is obtained and withdrawing arepresentative sample for analytical confirmation of active content, viscosity, andspecific gravity.

[0029] According to an exemplary embodiment of the present disclosure,determining an optimum emulsifier ratio based on the analytical results andsequentially adding emulsifiers Abamectin equivalent to 1.5 % w / w (C48H72O14),Pyriproxyfen equivalent to 9 % w / w (C20H19NO3), and Tolfenpyrad equivalent to 8 %w / w(C21H22ClN3O2) under constant stirring to achieve uniform emulsification.

[0030] According to another exemplary of the present disclosure, maintainingagitation for about two hours to complete emulsification and adjusting the final massusing co-solvent or main solvent to meet target composition.

[0031] According to another exemplary present disclosure, filtering the resultingmixture through a 5-10 μm cartridge filter to obtain a clarified filtrate.

[0032] According to another exemplary present disclosure, performing in-processcontrol (IPC) testing for appearance, viscosity, specific gravity, active content, andemulsion stability to ensure product conformity.

[0033] According to another exemplary present disclosure, filling the filtrate into precleaned, nitrogen-purged HDPE or aluminum bottles of 50 mL-5 L capacity, sealing,labeling, and packaging for dispatch.BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In the following, numerous specific details are set forth to provide a thoroughdescription of various embodiments. Certain embodiments may be practiced withoutthese specific details or with some variations in detail. In some instances, certainfeatures are described in less detail so as not to obscure other aspects. The level ofdetail associated with each of the elements or features should not be construed toqualify the novelty or importance of one feature over the others.

[0035] FIG. 1 is an example diagram depicting, the process for preparing Abamectinequivalent to 1.5 % w / w (C48H72O14), Pyriproxyfen equivalent to 9 % w / w(C20H19NO3), and Tolfenpyrad equivalent to 8 % w / w (C21H22ClN3O2) is illustrated inthe diagram, according to exemplary embodiments of the present disclosure.

[0036] FIG. 2 is an example flow diagram depicting, preparing stable emulsifiableconcentrate of Abamectin, Pyriproxyfen, and Tolfenpyrad for pest controlmanufacturing process flow chart, according to exemplary embodiments of thepresent disclosure.

[0037] FIG. 3 is an example flow diagram depicting a Method for preparing stableemulsifiable concentrate of Abamectin, Pyriproxyfen, and Tolfenpyrad for pestcontrol.DETAILED DESCRIPTION OF EXAMPLE EMBODIMENTS

[0038] It is to be understood that the present disclosure is not limited in itsapplication to the details of construction and the arrangement of components set forthin the following description or illustrated in the drawings. The present disclosure iscapable of other embodiments and of being practiced or of being carried out invarious ways. Also, it is to be understood that the phraseology and terminology usedherein is for the purpose of description and should not be regarded as limiting.

[0039] The use of "including", "comprising" or "having" and variations thereofherein is meant to encompass the items listed thereafter and equivalents thereof aswell as additional items. The terms "a" and "an" herein do not denote a limitation ofquantity, but rather denote the presence of at least one of the referenced item. Further,the use of terms "first", "second", and "third", and so forth, herein do not denote anyorder, quantity, or importance, but rather are used to distinguish one element fromanother.

[0040] Referring to FIG.1 diagram 100 depicting, the process of the process forpreparing Abamectin 1.50% w / w C48H72O14) + Pyriproxyfen 9.00% w / w C20H19NO3),+ Tolfenpyrad 8.00% w / w (C21H22ClN3O2) EC is illustrated in the diagram, accordingto exemplary embodiments of the present disclosure.

[0041] In accordance to the exemplary embodiment of the present disclosure, theexemplary method 100 commences at step, 102 and 106, explains initiating withfeeding the solvent from the feed tank into the formulation tank through a definedflow line. The feed tank is acting as a solvent reservoir, ensuring controlled andcontinuous transfer of the solvent to the formulation tank as per batch requirements.Thereafter at step 104, within the formulation tank, the raw materials including activeingredients, co-solvents, and emulsifiers are being charged sequentially in accordancewith the batch card. The tank is equipped with agitators or mechanical stirrers,enabling uniform mixing of all ingredients. The temperature and agitation speed arebeing regulated to ensure complete dissolution of actives and formation of ahomogeneous solution. The formulation tank is thus serving as the main blendingvessel for producing the emulsifiable concentrate. Thereafter at step 108, thehomogeneous mixing is achieved, the formulation is being transferred to the holdingtank using centrifugal pumps. The centrifugal pumps are maintaining a steady flowrate and pressure, facilitating smooth transfer of the formulation without causing airentrapment or phase separation. Thereafter at step 110 the holding tank is functioningas an intermediate storage unit, allowing for settling of any entrapped air orundissolved particles before filtration. From the holding tank, the formulation isbeing passed through a sparkler filter unit. Thereafter at step 112, the sparkler filter isoperating by removing fine particulates, impurities, or undissolved residues toachieve a clear, defect-free filtrate with improved visual and physical quality.Thereafter at step 114 and final step 116, the filtered product is then being directed tothe filling and packing line, where it is filled into pre-cleaned, nitrogen-purgedcontainers of predetermined capacities (e.g., 50 mL to 5 L). The filled containers arebeing sealed, labeled, and packed into corrugated cartons for final dispatch.

[0042] Referring to FIG. 2 diagram 200 depicting, The process for preparingAbamectin equivalent to 1.5 % w / w(C48H72O14), Pyriproxyfen equivalent to 9 % w / w(C20H19NO3), and Tolfenpyrad equivalent to 8 % w / w(C21H22ClN3O2) emulsifiableconcentrate (EC) is involving sequential steps ensuring uniformity, stability, and highformulation performance.

[0043] In accordance to the exemplary embodiment of the present disclosure, theexemplary method 100 commences at step, 202 collecting and preparing rawmaterials, including technicals, intermediates, solvents, and emulsifiers, according topredefined specifications. These materials are receiving and verifying under qualitystandards before being used for formulation. Thereafter at step 204, the process istransferring all approved raw materials into the formulation tank, and addingtechnicals, intermediates, and solvents in specified ratios. The mixture is agitatingcontinuously for about three hours, ensuring complete dissolution and forming ahomogeneous mixture. Thereafter at step 206, obtaining a uniform blend, the processproceeds by adding emulsifiers to the homogeneous raw material mixture. Theemulsifier addition is continuing with controlled stirring for approximately two hours,ensuring proper emulsification and improved dispersion stability. Thereafter at step208, once the formulation is completed, the batch is subjecting to quality controltesting, including physical property evaluation, emulsion stability, and activeingredient assay, thereby ensuring compliance with required specifications. Finalthereafter at step 210 after successful evaluation, the finished product is proceeding tothe clearance stage, where it is filling into containers of 1 L, 500 mL, 250 mL, and100 mL capacity, followed by sealing, labeling, and packaging for distribution. Theoverall process ensures achieving consistent product quality, enhancing storagestability, and improving field performance of the emulsifiable concentrateformulation.

[0044] Referring to FIG.3 is a diagram 300 is a flow diagram, method for preparingstable emulsifiable concentrate of Abamectin, Pyriproxyfen, and Tolfenpyrad for pestcontrol. The method 300 may be carried out in the context of the FIG1, FIG2. Theexemplary method 300 commences at step, 302 explains beginning the process byreceiving technicals, intermediates, solvents, and emulsifiers as per the materialrequisition for the intended batch. Thereafter at step 304, Performing analyticaltesting for assessing purity and physical properties of all received materials, includingassay, moisture content, and pH evaluation, to ensure compliance with predefinedquality standards. Thereafter at step 306, Approving materials meeting specificationlimits for further processing and rejecting nonconforming materials, thereby ensuringonly qualified inputs enter the production process. Thereafter at step 308, Preparing abatch card by defining batch size (2 KL / 3 KL / 5 KL), composition ratios, sequenceof addition, equipment to be used, and operator authorization, enabling standardizedmanufacturing control. Thereafter at step 310, issuing materials to production basedon QC-approved specifications and corresponding batch documentation, ensuringtraceable material movement. Thereafter at step 312, Charging approximately 70-80% of the total solvent into the formulation or reactor tank according to the batchcard instructions. Thereafter at step 314, Initiating agitation at 150-250 rpm to ensureuniform solvent circulation and promote consistent mixing within the tank. Thereafterat step 316, Maintaining temperature between 25°C and 30°C during the initialagitation phase to prevent solvent evaporation and ensure stable mixing conditions.Thereafter at step 318, Adding antioxidants and UV absorbers into the solvent undercontinuous agitation to enhance formulation stability and shelf-life. Thereafter at step320, continuing agitation for 20-30 minutes until complete dissolution ofantioxidants and UV absorbers is achieved, forming a clear and stable base solution.Thereafter at step 322, verifying the clarity of the solution visually before proceedingto the next processing stage. Thereafter at step 324, sequentially adding activeingredients - Abamectin equivalent to 1.5 % w / w(C48H72O14), Pyriproxyfenequivalent to 9 % w / w (C20H19NO3), and Tolfenpyrad equivalent to 8 %w / w(C21H22ClN3O2) (pre-blended with co-solvent) - into the formulation tank whilemaintaining temperature below 35°C to avoid degradation of actives. Thereafter atstep 326, continuing agitation until a clear, homogeneous mixture of actives isobtained, ensuring uniform distribution throughout the solvent matrix. Thereafter atstep 328 withdrawing a representative sample after complete dissolution of actives foranalytical testing to confirm proper solubilization. Thereafter at step 330 analyzingthe sample for parameters such as active content, specific gravity, viscosity, andhomogeneity, verifying formulation accuracy. Thereafter at step 332, determining theoptimum emulsifier ratio based on analytical findings to achieve maximum stabilityand emulsification efficiency. Thereafter at step 334, sequentially adding emulsifiersAbamectin equivalent to 1.5 % w / w (C48H72O14), Pyriproxyfen equivalent to 9 % w / w(C20H19NO3), and Tolfenpyrad equivalent to 8 % w / w (C21H22ClN3O2) under constantstirring to promote uniform dispersion within the active mixture. Thereafter at step336, continuing agitation for approximately two hours to ensure completeemulsification and uniform consistency. Thereafter at step 338, Adjusting the finalmass using co-solvent or main solvent as required to meet target composition andvolume specifications. Thereafter at step 340, Filtering the mixture through a 5-10μm cartridge filter to eliminate particulate matter and ensure product clarity.Thereafter at step 342, collecting the filtrate in a clean, labeled storage tank,maintaining a contamination-free environment. Thereafter at step 344 Conductingreal-time in-process control (IPC) monitoring by measuring appearance, specificgravity, viscosity, acidity / alkalinity, flash point, active assay, emulsion stability, andmoisture content, ensuring process integrity, Thereafter at step 346, Ensuring the finalyield of the formulation is greater than or equal to 99%, confirming efficient materialutilization and minimal loss. Thereafter at step 348, Performing final QC testing onthe finished formulation to verify conformity with chemical and physicalspecifications. Thereafter at step 350, approving the batch for packaging uponsatisfactory QC results, ensuring compliance before release. Thereafter at step 352,filling the filtrate into pre-cleaned, nitrogen-purged bottles (50 mL to 5 L) usingcalibrated filling equipment to prevent oxidation and contamination. Thereafter atstep 354, Sealing and labeling bottles with batch number, manufacturing date, andexpiry details to maintain traceability and product identity. Thereafter at step 356,Packing primary containers into corrugated boxes (5 L / 10 L) according to packagingguidelines, ensuring safe transport. Thereafter at step 358, including product leafletsand Material Safety Data Sheets (MSDS) in each shipping carton to provide handlingand safety information. Thereafter at step 360, Sealing and labeling corrugatedcartons for dispatch, maintaining compliance with shipping standards. Thereafter atstep 362, Conducting QA document review to verify batch documentation, qualityresults, and packaging readiness. Finally thereafter at step 364, clearing the batch fordispatch post-QA approval and maintaining traceability records for regulatorycompliance and quality assurance.

[0045] In accordance with one or more exemplary embodiments of the presentdisclosure, the solvents comprise aromatic hydrocarbons, glycol ethers, or aliphaticesters compatible with all actives.

[0046] In accordance with one or more exemplary embodiments of the presentdisclosure, the temperature during step (d) is maintained between 28 °C and 35 °C toensure complete solubilization of actives.

[0047] In accordance with one or more exemplary embodiments of the presentdisclosure, the viscosity of the final formulation is maintained between 200 and 600cP and specific gravity between 0.95-1.05 g / mL.

[0048] In accordance with one or more exemplary embodiments of the presentdisclosure, the final yield of the formulation is ≥ 99 %, achieved through optimizationof agitation time and solvent addition sequence.

[0049] In accordance with one or more exemplary embodiments of the presentdisclosure, the filtration step (h) removes particulates > 5 μm, producing atransparent concentrate free from undissolved residues.

[0050] In accordance with one or more exemplary embodiments of the presentdisclosure, the emulsifier system includes nonionic and anionic surfactants selectedfrom polyoxyethylene alkyl ethers, calcium dodecylbenzenesulfonate, and castor-oilethoxylate.

[0051] In accordance with one or more exemplary embodiments of the presentdisclosure, the process is executed for batch sizes of 2 KL, 3 KL, or 5 KL definedthrough a batch-card system ensuring material traceability.

[0052] In accordance with one or more exemplary embodiments of the presentdisclosure, further comprising performing QA document review, labeling with batchnumbers, and packing sealed containers into corrugated boxes including leaflets andMSDS prior to dispatch.

[0053] In accordance with one or more exemplary embodiments of the presentdisclosure, A stable emulsifiable concentrate (EC) composition produced accordingto the method of claim 1, comprising:Abamectin 1.5 % w / w 1.5 % w / w (C48H72O14 (mixture of B1a and B1bcomponents),Pyriproxyfen 9.0 % w / w (C20H19NO),Tolfenpyrad 8.0 % w / w(C21H22ClN3O2),a solvent system selected from aromatic hydrocarbons, glycol ethers, oraliphatic esters,emulsifiers A, B, and C in optimized ratio for emulsification stability, andadditives comprising antioxidants and UV absorbers;Wherein the composition forms a clear, homogeneous solution exhibiting emulsionstability >: 90 % after 0.5 h and 24 h, and retains chemical and physical integrityunder accelerated storage at 54 °C for 14 days.

[0054] Furthermore, the described features, structures, or characteristics of thedisclosure may be combined in any suitable manner in one or more embodiments. Inthe above description, numerous specific details are provided such as examples ofprogramming, software modules, user selections, network transactions, databasequeries, database structures, hardware modules, hardware circuits, hardware chips,etc., to provide a thorough understanding of embodiments of the disclosure.

[0055] Although the present disclosure has been described in terms of certainpreferred embodiments and illustrations thereof, other embodiments andmodifications to preferred embodiments may be possible that are within theprinciples and spirit of the invention. The above descriptions and figures are thereforeto be regarded as illustrative and not restrictive.

[0056] Thus the scope of the present disclosure is defined by the appended claimsand includes both combinations and sub-combinations of the various featuresdescribed hereinabove as well as variations and modifications thereof, which wouldoccur to persons skilled in the art upon reading the foregoing description.

Claims

1. A Method for preparing stable emulsifiable concentrate of abamectin, Pyriproxyfen, and Tolfenpyrad for pest control, comprising: (a) receiving and quality-checking technical-grade actives, solvents, and emulsifiers for purity, assay, and moisture compliance; (b) charging about 70-80 % of the total solvent into a formulation tank and initiating agitation at 150-250 rpm while maintaining temperature between 25 °C and 30 °C to form a uniform solvent base; (c) adding antioxidants and UV absorbers under continuous stirring until completely dissolved to form a clear base solution; (d) sequentially introducing Abamectin equivalent to 1.5 % w / w(C48H72O14), Pyriproxyfen equivalent to 9 % w / w (C20H19NO3), and Tolfenpyrad equivalent to 8 % w / w(C21H22ClN3O2) into the solvent base while maintaining temperature below 35 °C to prevent degradation; (e) continuing agitation until a clear, homogeneous solution of actives is obtained and withdrawing a representative sample for analytical confirmation of active content, viscosity, and specific gravity; (f) determining an optimum emulsifier ratio based on the analytical results and sequentially adding emulsifiers Abamectin equivalent to 1.5 % w / w(C48H72O14), Pyriproxyfen equivalent to 9 % w / w (C20H19NO3), and Tolfenpyrad equivalent to 8 % w / w(C21H22ClN3O2) under constant stirring to achieve uniform emulsification; (g) maintaining agitation for about two hours to complete emulsification and adjusting the final mass using cosolvent or main solvent to meet target composition; (h) filtering the resulting mixture through a 5-10 μm cartridge filter to obtain a clarified filtrate; (i) performing in-process control (IPC) testing for appearance, viscosity, specific gravity, active content, and emulsion stability to ensure product conformity; and; (j) filling the filtrate into pre-cleaned, nitrogen-purged HDPE or aluminum bottles of 50 mL-5 L capacity, sealing, labeling, and packaging for dispatch.

2. The method of claim 1, wherein the solvents comprise aromatic hydrocarbons, glycol ethers, or aliphatic esters compatible with all actives.

3. The method of claim 1, wherein the temperature during step (d) is maintained between 28 °C and 35 °C to ensure complete solubilization of actives.

4. The method of claim 1, wherein the viscosity of the final formulation is maintained between 200 and 600 cP and specific gravity between 0.95-1.05 g / mL.

5. The method of claim 1, wherein the final yield of the formulation is ≥ 99 %, achieved through optimization of agitation time and solvent addition sequence.

6. The method of claim 1, wherein the filtration step (h) removes particulates > 5 μm, producing a transparent concentrate free from undissolved residues..

7. The method of claim 1, wherein the emulsifier system includes nonionic and anionic surfactants selected from polyoxyethylene alkyl ethers, calcium dodecylbenzenesulfonate, and castor-oil ethoxylate.

8. The method of claim 1, wherein the process is executed for batch sizes of 2 KL, 3 KL, or 5 KL defined through a batch-card system ensuring material traceability.

9. The method of claim 1, further comprising performing QA document review, labeling with batch numbers, and packing sealed containers into corrugated boxes including leaflets and MSDS prior to dispatch.

10. A stable emulsifiable concentrate (EC) composition produced according to the method of claim 1, comprising: Abamectin 1.5 % w / w (C48H72O14), Pyriproxyfen 9.0 % w / w (C20H19NO3), Tolfenpyrad 8.0 % w / w (C21H22ClN3O2), a solvent system selected from aromatic hydrocarbons, glycol ethers, or aliphatic esters, emulsifiers A, B, and C in optimized ratio for emulsification stability, and additives comprising antioxidants and UV absorbers; Wherein the composition forms a clear, homogeneous solution exhibiting emulsion stability > 90 % after 0.5 h and 24 h, and retains chemical and physical integrity under accelerated storage at 54 °C for 14 days.